Guidance from risk calculators and guidelines, such as PREVENT, may support integrating biomarker information into risk assessments and shared decision‑making for preventive therapies.

Experts acknowledge potential cost and coverage barriers but note growing evidence and treatment options that may make biomarker testing increasingly relevant in preventive cardiology.

Although not part of routine screening guidelines, these tests are available at many labs on request and could aid in early risk detection and personalized preventive decisions.

Despite not being standard in routine screening, these tests can be ordered at most labs and may support personalized preventive care when traditional risk factors are inconclusive.

Clinicians may consider these biomarkers alongside genetic risk scores and coronary artery calcium scans as part of a broader toolkit for assessing heart attack risk, with attention to cost and coverage.

Elevated results were defined as the top 20% for each marker, with analyses adjusting for conventional risk factors.

The analysis involved 306,183 adults free of heart disease at baseline, with 10,824 events (3.5%) of heart attack during follow-up.

Lead researcher described the trio as pieces of a puzzle that together illuminate heart attack risk.

These results were presented at a medical meeting; they remain preliminary until peer‑reviewed publication, and further research is needed to integrate them into standard practice.

A three-pronged blood test measuring lipoprotein(a) (Lp(a)), remnant cholesterol, and high-sensitivity C-reactive protein (hsCRP) may identify individuals at markedly higher risk for heart attack, with risk rising nearly threefold when all three markers are in the highest ranges.

Together, these three biomarkers provide a clearer picture of cardiovascular risk than any single marker, capturing genetic factors, inflammation, and cholesterol abnormalities.

Each biomarker reflects a different pathway to cardiovascular disease—genetics (Lp(a)), cholesterol metabolism (remnant cholesterol), and inflammation (hsCRP)—and their combination could improve early identification and personalized prevention.

The findings are preliminary until published in a peer‑reviewed journal, and clinicians may weigh cost and insurance coverage when incorporating the tests into care.

Tests can be conducted using available lab measures (Lp(a) and hsCRP) and remnant cholesterol calculated from standard lipid panels, potentially making the approach accessible in routine care.

The study analyzed data from more than 300,000 UK Biobank participants followed for a median of 15 years, linking the three biomarkers to heart attack risk.

Across the UK Biobank cohort, risk rose stepwise: all three high markers nearly tripled risk, two high markers doubled risk, and one high marker increased risk by about 45%.

A stepwise pattern emerged: all three biomarkers high confer nearly threefold risk; two high markers double the risk; a single elevated marker increases risk by roughly 45%.

Lp(a) is genetically influenced and linked to arterial blockage; remnant cholesterol can be missed by standard tests yet promotes atherogenesis; hsCRP signals systemic inflammation tied to arterial damage.

While promising, the study is observational and based on an abstract; generalizability to diverse populations needs further research and formal publication.